adding therapeutic value

Photo_Michel_Souchet_2Espacement_President_HomepageHarmonic Pharma has developed a unique polypharmacology based know-how to characterize new uses of safe drugs. Our approach allows an accelerated pre-clinical investigation in the newly identified indication while advancing drug candidates to a de-risked clinical development sooner.

Oncology is one of the major priorities of the company.

Michel Souchet, PhD – CEO

about polypharmacology


harmonic pharma

Harmonic Pharma is the very first company developing and applying the polypharmacology paradigm to strategic therapeutic areas such as oncology. The company’s know-how derives from a breakthrough innovation  allowing to revisit safe drugs and drug candidates.

About us


Harmonic Pharma’s pipeline comprises a selection of drugs with a known safety profile that can be evaluated rapidly in phase IIb, once efficacy in the novel selected indication is demonstrated.

Read more



World Cancer Congress
13 July 2016


Harmonic Pharma will be part of the 2016 World Cancer Congress in Paris ! You are welcome to visit us at booth #23 of the global village.

Read more

View all news

Strategic partnering

Investment key factors:

  • Highly innovative technology for revisiting drugs allowing a robust transition from a novel mechanism of action to drug candidates
  • Team members with complementary and experienced backgrounds
  • Reducing time to clinical trial
  • Strong IP positions
  • Partnering with experts institutions in oncology

join us